A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin

References

• Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20:146–59.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57:647–53.
   PubMed Web of Science ®Google Scholar
• Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849–55.
   PubMed Web of Science ®Google Scholar
• Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer. 2006;106:361–5.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02 Trial Investigators). N Engl J Med. 2010;362:1273–81.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74.
   PubMed Web of Science ®Google Scholar
• Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology. 2009;76:254–61.
   PubMed Web of Science ®Google Scholar
• Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, et al. A phase Π study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2012;48:196–201.
   PubMed Web of Science ®Google Scholar
• Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, et al. Phase Π study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs. 2011;29:1066–72.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs. 2012;30:708–13.
   PubMed Web of Science ®Google Scholar
• Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50–5.
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11:1142–8.
   PubMed Web of Science ®Google Scholar
• Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliarytumours. Eur J Cancer. 1995;31:1594–8.
   Web of Science ®Google Scholar
• Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase Π study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543–8.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
   PubMed Web of Science ®Google Scholar
• Novarino AM, Satolli MA, Chiappino I, Giacobino A, Napoletano R, Ceccarelli M, et al. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer. Am J Clin Oncol. 2012;9 (abstract: PMID: 22781390).
   Web of Science ®Google Scholar
• Kautio AL, Haanpää M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and National Cancer Institute – Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res. 2011;31:3493–6.
   PubMed Web of Science ®Google Scholar
• Simon R. How large should a phase Π trial of a new drug be? Cancer Treat Rep. 1987;71:1079–85.
   PubMedGoogle Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11:48–54.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181–8.
   PubMed Web of Science ®Google Scholar
• Katayose Y, Ohtsuka H, Kitamura Y, Masuda K, Nakagawa K, Yamamoto K, et al. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. Hepatogastroenterology. 2012;59:691–5.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, et al. Phase Π Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06–101. Oncologist. 2012;17:13.
   PubMed Web of Science ®Google Scholar
• Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mössner J, et al. Imatinibmesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase Π study. Onkologie. 2011;34:469–70.
   PubMed Web of Science ®Google Scholar
• He XR, Wu XP. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro. Chin Med Sci J. 2008;23:54–9.
   PubMedGoogle Scholar
• Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentrerandomised phase II study – The UK ABC-01 Study. Br J Cancer. 2009;101:621–7.
   PubMed Web of Science ®Google Scholar
• Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332–8.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181–8.
   Google Scholar